Capital Advisors Ltd
SMMT icon

Capital Advisors Ltd’s Summit Therapeutics SMMT Stock Holding History

Capital Advisors Ltd’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$0 Sell
1
-84
-99% -$1.26K ﹤0.01% 1637
2026
Q2 		$1K Buy
85
+84
+8,400% +$1.49K ﹤0.01% 1298
2026
Q1 		$0 Buy
+1
New +$16 ﹤0.01% 1583

Other funds holding SMMT

Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Hohimer Wealth Management
Hohimer Wealth Management Seattle, Washington $1.03B AUM 25.45% 1-Year Est. Return
Griffin Asset Management
Griffin Asset Management New York $934M AUM 18.69% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Wealth Management Partners
Wealth Management Partners Tucson, Arizona $426M AUM 43.17% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Capital Advisors Ltd's SMMT Position: Q3 2026 in Review

Capital Advisors Ltd reduced its Summit Therapeutics (SMMT) stake by 99% in Q3 2026, selling an estimated $1.26K and leaving 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1637.

Capital Advisors Ltd first reported a position in SMMT in Q1 2026 and has held it in 3 quarters since. The position peaked at $1K in Q2 2026. 89 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • Capital Advisors Ltd held 1 share of Summit Therapeutics worth $0 as of Q3 2026.
  • Capital Advisors Ltd sold 84 Summit Therapeutics shares in Q3 2026, an estimated $1.26K.
  • Summit Therapeutics made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q3 2026, its #1637 holding.
  • Capital Advisors Ltd first reported a position in Summit Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Capital Advisors Ltd's Summit Therapeutics position peaked at $1K in Q2 2026.
  • 89 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Capital Advisors Ltd's 13F filing for Q3 2026, filed 27 Oct 2026.